ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

8 links0 made here, not in the record15 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT01304784A Study of MM-111 inCombination With MultipleTreatments in Patients WithHER2 Positive CancerMerrimack PharmaceuticalsPhase 1 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSHER-2 Gene AmplificationNo longer in the registry's filing›Nov 14 · Rule based · Not readNot readDRUGSCisplatinEntry “Cisplatin, Capecitabine, Trast…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCapecitabineEntry “Cisplatin, Capecitabine, Trast…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrastuzumabEntry “Cisplatin, Capecitabine, Trast…›Nov 2 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedTestedMM-111Entry “Cisplatin, Capecitabine, Trast…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLapatinibEntry “Lapatinib +/- Trastuzumab and …›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPaclitaxelEntry “Paclitaxel, Trastuzumab and MM…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedDocetaxelEntry “Docetaxel, trastuzumab and MM-…›Nov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Cisplatin

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Cisplatin, Capecitabine, Trastuzumab and MM-111”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2CisplatinClaude Opus 5.5TestedCurrent
Nov 2CapecitabineClaude Opus 5.5TestedCurrent
Nov 2TrastuzumabClaude Opus 5.5Background · partnerCurrent
Nov 2MM-111Claude Opus 5.5TestedCurrent
Nov 2LapatinibClaude Opus 5.5TestedCurrent
Nov 2PaclitaxelClaude Opus 5.5TestedCurrent
Nov 2DocetaxelClaude Opus 5.5TestedCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 14HER-2 Gene AmplificationRule based · condition-kind ruleNot readCurrent
Nov 18CisplatinRule based · role ruleTestedAgrees
Nov 18CapecitabineRule based · role ruleTestedAgrees
Nov 18TrastuzumabRule based · role ruleTestedCurrent
Nov 18MM-111Rule based · role ruleTestedAgrees
Nov 18LapatinibRule based · role ruleTestedAgrees
Nov 18PaclitaxelRule based · role ruleTestedAgrees
Nov 18DocetaxelRule based · role ruleTestedAgrees

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.